FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386032554> ?p ?o ?g. }

• W4386032554 abstract "Introduction PI3K/AKT signaling pathway is upregulated in a broad spectrum of cancers. Among the class I PI3Ks (PI3Kδ/β/δ isoforms), PI3Kδ has been implicated in hematologic cancers and solid tumors. Alternative splicing is a post-transcriptional process for acquiring proteomic diversity in eukaryotic cells. Emerging evidence has highlighted the involvement of aberrant mRNA splicing in cancer development/progression. Methods Our previous studies revealed that PIK3CD-S is an oncogenic splice variant that promotes tumor aggressiveness and drug resistance in prostate cancer (PCa). To further evaluate the potential of utilizing PI3Kδ-S (encoded from PIK3CD-S ) as a cancer biomarker and/or drug target, comprehensive analyses were performed in a series of patient samples and cell lines derived from endocrine/solid tumors. Specifically, IHC, immunofluorescence, western blot and RT-PCR assay results have demonstrated that PI3Kδ isoforms were highly expressed in endocrine/solid tumor patient specimens and cell lines. Results Differential PIK3CD-S/PIK3CD-L expression profiles were identified in a panel of endocrine/solid tumor cells. SiRNA knockdown of PIK3CD-L or PIK3CD-S differentially inhibits AKT/mTOR signaling in PCa, breast, colon and lung cancer cell lines. Moreover, siRNA knockdown of PTEN increased PI3Kδ levels and activated AKT/mTOR signaling, while overexpression of PTEN reduced PI3Kδ levels and inhibited AKT/mTOR signaling in cancer cells. Intriguingly, PI3Kδ-S levels remained unchanged upon either siRNA knockdown or overexpression of PTEN. Taken together, these results suggested that PTEN negatively regulates PI3Kδ-L and its downstream AKT/mTOR signaling, while PI3Kδ-S promotes AKT/mTOR signaling without regulation by PTEN. Lastly, PI3Kδ inhibitor Idelalisib and SRPK1/2 inhibitor SRPIN340 were employed to assess their efficacies on inhibiting the PI3Kδ-expressing endocrine/solid tumors. Our results have shown that Idelalisib effectively inhibited PI3Kδ-L (but not PI3Kδ-S) mediated AKT/mTOR signaling. In contrast, SRPIN340 reversed the aberrant mRNA splicing, thereby inhibiting AKT/mTOR signaling. In-vitro functional assays have further demonstrated that a combination of Idelalisib and SRPIN340 achieved a synergistic drug effect (with drastically reduced cell viabilities/growths of tumor spheroids) in inhibiting the advanced tumor cells. Conclusion In summary, our study has suggested a promising potential of utilizing PI3Kδ-S (an oncogenic isoform conferring drug resistance and exempt from PTEN regulation) as a prognostic biomarker and drug target in advanced endocrine cancers." @default.
• W4386032554 created "2023-08-22" @default.
• W4386032554 creator A5059355908 @default.
• W4386032554 creator A5060130177 @default.
• W4386032554 creator A5082769434 @default.
• W4386032554 date "2023-08-21" @default.
• W4386032554 modified "2023-09-27" @default.
• W4386032554 title "Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers" @default.
• W4386032554 cites W1693454377 @default.
• W4386032554 cites W1734521060 @default.
• W4386032554 cites W1904402326 @default.
• W4386032554 cites W1990785257 @default.
• W4386032554 cites W2001952613 @default.
• W4386032554 cites W2009886463 @default.
• W4386032554 cites W2011920499 @default.
• W4386032554 cites W2014096417 @default.
• W4386032554 cites W2027623923 @default.
• W4386032554 cites W2029022814 @default.
• W4386032554 cites W2054318449 @default.
• W4386032554 cites W2060383308 @default.
• W4386032554 cites W2072697288 @default.
• W4386032554 cites W2087835012 @default.
• W4386032554 cites W2093308768 @default.
• W4386032554 cites W2093720054 @default.
• W4386032554 cites W2115706649 @default.
• W4386032554 cites W2120021279 @default.
• W4386032554 cites W2127388402 @default.
• W4386032554 cites W2129220997 @default.
• W4386032554 cites W2142781168 @default.
• W4386032554 cites W2146414563 @default.
• W4386032554 cites W2151258296 @default.
• W4386032554 cites W2154608911 @default.
• W4386032554 cites W2155804510 @default.
• W4386032554 cites W2167197826 @default.
• W4386032554 cites W2729691328 @default.
• W4386032554 cites W2795174081 @default.
• W4386032554 cites W2897338348 @default.
• W4386032554 cites W2901534288 @default.
• W4386032554 cites W2909792245 @default.
• W4386032554 cites W2942538421 @default.
• W4386032554 cites W2953064112 @default.
• W4386032554 cites W2966296683 @default.
• W4386032554 cites W2976412784 @default.
• W4386032554 cites W2979022664 @default.
• W4386032554 cites W3016333653 @default.
• W4386032554 cites W3036692714 @default.
• W4386032554 cites W3093050257 @default.
• W4386032554 cites W3207794695 @default.
• W4386032554 cites W4220960607 @default.
• W4386032554 cites W4291885055 @default.
• W4386032554 cites W4293094513 @default.
• W4386032554 cites W4321377844 @default.
• W4386032554 doi "https://doi.org/10.3389/fendo.2023.1190479" @default.
• W4386032554 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37670888" @default.
• W4386032554 hasPublicationYear "2023" @default.
• W4386032554 type Work @default.
• W4386032554 citedByCount "0" @default.
• W4386032554 crossrefType "journal-article" @default.
• W4386032554 hasAuthorship W4386032554A5059355908 @default.
• W4386032554 hasAuthorship W4386032554A5060130177 @default.
• W4386032554 hasAuthorship W4386032554A5082769434 @default.
• W4386032554 hasBestOaLocation W43860325541 @default.
• W4386032554 hasConcept C104317684 @default.
• W4386032554 hasConcept C121608353 @default.
• W4386032554 hasConcept C173396325 @default.
• W4386032554 hasConcept C185592680 @default.
• W4386032554 hasConcept C194583182 @default.
• W4386032554 hasConcept C2777609662 @default.
• W4386032554 hasConcept C2780192828 @default.
• W4386032554 hasConcept C502942594 @default.
• W4386032554 hasConcept C53345823 @default.
• W4386032554 hasConcept C54355233 @default.
• W4386032554 hasConcept C55493867 @default.
• W4386032554 hasConcept C62478195 @default.
• W4386032554 hasConcept C75217442 @default.
• W4386032554 hasConcept C81885089 @default.
• W4386032554 hasConcept C86554907 @default.
• W4386032554 hasConcept C86803240 @default.
• W4386032554 hasConcept C95444343 @default.
• W4386032554 hasConceptScore W4386032554C104317684 @default.
• W4386032554 hasConceptScore W4386032554C121608353 @default.
• W4386032554 hasConceptScore W4386032554C173396325 @default.
• W4386032554 hasConceptScore W4386032554C185592680 @default.
• W4386032554 hasConceptScore W4386032554C194583182 @default.
• W4386032554 hasConceptScore W4386032554C2777609662 @default.
• W4386032554 hasConceptScore W4386032554C2780192828 @default.
• W4386032554 hasConceptScore W4386032554C502942594 @default.
• W4386032554 hasConceptScore W4386032554C53345823 @default.
• W4386032554 hasConceptScore W4386032554C54355233 @default.
• W4386032554 hasConceptScore W4386032554C55493867 @default.
• W4386032554 hasConceptScore W4386032554C62478195 @default.
• W4386032554 hasConceptScore W4386032554C75217442 @default.
• W4386032554 hasConceptScore W4386032554C81885089 @default.
• W4386032554 hasConceptScore W4386032554C86554907 @default.
• W4386032554 hasConceptScore W4386032554C86803240 @default.
• W4386032554 hasConceptScore W4386032554C95444343 @default.
• W4386032554 hasFunder F4320337354 @default.
• W4386032554 hasLocation W43860325541 @default.
• W4386032554 hasLocation W43860325542 @default.
• W4386032554 hasOpenAccess W4386032554 @default.

• next